Quick Answer
Sarepta Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $801.28 million for the year ending 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -27.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Sarepta Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), Sarepta Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 7,059.4%.
- Historical annual values: Fiscal year 2025: $801.28 million | Fiscal year 2024: $1.10 billion | Fiscal year 2023: $428.43 million | Fiscal year 2022: $966.78 million | Fiscal year 2021: $2.12 billion | Fiscal year 2020: $1.50 billion | Fiscal year 2019: $835.08 million | Fiscal year 2018: $370.83 million | Fiscal year 2017: $599.69 million | Fiscal year 2016: $122.42 million | Fiscal year 2015: $80.30 million | Fiscal year 2014: $73.55 million | Fiscal year 2013: $256.97 million | Fiscal year 2012: $187.66 million | Fiscal year 2011: $39.90 million | Fiscal year 2010: $33.59 million | Fiscal year 2009: $48.28 million | Fiscal year 2008: $11.19 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: